Incyte Corporation's Fiscal Year is From January To December.
The item "Price-To-Cashflow-Ratio" stands at 13.31 as of 09/30/2025, the lowest value since 09/30/2024.
As of the end of Incyte Corporation's third quarter, the item "Price To Cashflow Ratio" stands at 13.31. This represents a decrease of -3.12 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -115.90 compared to the value the year prior.
The Serie's long term average value is 13.34. It's latest available value, on 09/30/2025, is -0.0354 lower, compared to it's long term average value.
The Serie's change from it's minimum value, on 06/30/2024, to it's latest available value, on 09/30/2025, is +211.35 .
The Serie's change from it's maximum value, on 09/30/2024, to it's latest available value, on 09/30/2025, is -115.90 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Cashflow Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price To Cashflow Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Price To Cashflow Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price To Cashflow Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Cashflow Ratio | 280,205,508,085.11 |